Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma
| Autor: | Warner W Carr, Mirna McDonald, Paige Meizlik |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Spirometry Adult Male medicine.medical_specialty Adolescent Placebo Antibodies Monoclonal Humanized law.invention Placebos Young Adult Randomized controlled trial Quality of life Reslizumab Double-Blind Method law Internal medicine Post-hoc analysis Eosinophilia medicine Immunology and Allergy Humans Anti-Asthmatic Agents Young adult Child Lung Asthma medicine.diagnostic_test business.industry General Medicine Middle Aged medicine.disease respiratory tract diseases Quality of Life Administration Intravenous Female business medicine.drug |
| Zdroj: | Allergy and asthma proceedings. 40(4) |
| ISSN: | 1539-6304 |
| Popis: | Background: Spirometric lung age expresses lung function relative to chronological age. It has been effective in encouraging smoking cessation and has been used in the assessment of asthma. Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, is approved as add-on therapy for adults with severe asthma and elevated blood eosinophils. Objective: To assess the effect of reslizumab versus placebo on the change in lung age over 52 weeks and the correlation between change in lung age and quality of life in moderate-to-severe asthma. Methods: This was a post hoc analysis of two randomized, double-blind, placebo-controlled trials. Patients ages 12-75 years with moderate-to-severe, inadequately controlled asthma and elevated blood eosinophils received intravenous reslizumab 3.0 mg/kg or placebo every 4 weeks for 1 year. Spirometry was performed every 4 weeks, and the Asthma Quality of Life Questionnaire (AQLQ) score was assessed at baseline and weeks 16, 32, and 52. Results: Mean improvement in lung-age deficit at week 52 was -8.73 years for reslizumab versus -3.80 years for placebo, a treatment difference of 5 years (p www.clinicaltrials.gov . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|